about
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7Mammalian WDR12 is a novel member of the Pes1-Bop1 complex and is required for ribosome biogenesis and cell proliferationRecognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus.Stringent doxycycline-dependent control of gene activities using an episomal one-vector system.Structural and functional insights into 5′-ppp RNA pattern recognition by the innate immune receptor RIG-I5'-Triphosphate RNA is the ligand for RIG-ILatent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells.Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphatesRIG-I detects triphosphorylated RNA of Listeria monocytogenes during infection in non-immune cellsA human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNAsiRNA and isRNA: two edges of one sword.c-MYC impairs immunogenicity of human B cells.RNA recognition via TLR7 and TLR8.Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.Accessing the therapeutic potential of immunostimulatory nucleic acids.Approaching the RNA ligand for RIG-I?The chase for the RIG-I ligand--recent advances.Exosomes as nucleic acid nanocarriers.Master sensors of pathogenic RNA - RIG-I like receptors.Discriminating self from non-self in nucleic acid sensing.G-rich DNA-induced stress response blocks type-I-IFN but not CXCL10 secretion in monocytes.RIG-I activation induces the release of extracellular vesicles with antitumor activity.Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production.Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA.RIG-I Activation Protects and Rescues from Lethal Influenza Virus Infection and Bacterial Superinfection.C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.Active NF-kappaB signalling is a prerequisite for influenza virus infection.RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids.Enzymatic synthesis and purification of a defined RIG-I ligand.MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes.Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8.SiRNA delivery with exosome nanoparticles.Delivery with polycations extends the immunostimulant Ribomunyl® into a potent antiviral Toll-like receptor 7/8 agonistMonocyte-Mediated Inhibition of TLR9-Dependent IFN- Induction in Plasmacytoid Dendritic Cells Questions Bacterial DNA as the Active Ingredient of Bacterial LysatesHuman TLR8 Senses RNA From -Infected Red Blood Cells Which Is Uniquely Required for the IFN-γ Response in NK Cells
P50
Q24295641-1E30BBDA-E85A-452B-BAC0-77D0E04BAA93Q24310054-2FD85ED6-E8A5-47BB-9D55-5DD4AAF4671AQ24310706-EA2923F0-919D-4E78-B644-F8C5C356808EQ24812741-AC61BDD8-3818-44EC-AA93-2F52A15D33A7Q27662820-9210A9DD-16B7-4175-822A-E8F52021305EQ28131726-750EEE96-A2F6-42E5-A68D-4B093AE9F9FFQ33724152-6A063209-6325-4472-B930-BF0C41A08984Q34357042-2FF0F70C-9C41-4018-ABB5-050C401CDB0BQ34362314-15D44A6B-68AD-43A2-9760-E3BDDEEFB08AQ34709924-0EC633EE-033D-4FC8-A452-DEE3DD8103A6Q34936725-1026CD7C-5A29-4F4D-8495-26BAE06702AEQ36550881-1DF9159A-F888-4328-A749-0178F180861DQ36786058-98A9DB01-4409-480A-A441-F3BAE3856509Q37028825-FCFE9D86-051D-4E9D-B691-1DF83F0C01ABQ37092673-282AAA37-A005-4231-BE21-72315437E9D0Q37192244-45092C85-B674-451D-8F74-F634909AB776Q37225978-B5F724E5-EEDE-47B4-B978-31762C6BD7A7Q37361445-9F791A0B-6562-412E-967D-720674589AC7Q37749473-0F56578A-0BAA-4100-8D77-EF02C0A497E0Q38023105-4B648A26-AD97-4EB4-BF9E-2053A95C8C6EQ38125018-0FA8BD4E-1AFA-42D4-AC60-6C645B5898DCQ38907820-82B0BE39-5B3B-4477-87F7-B5A58561F134Q39110425-E3912277-51FF-4B6F-86A3-7D15BDB37344Q39181844-E8AD38EE-7927-42AC-B94F-E00516DA2DF1Q39198219-59487BF3-8BF1-40B5-AE98-3BB3B3BDFBBAQ39774272-AABC8BDD-C827-41BB-9353-BCA2DAC45D54Q39822897-389374B2-8C49-44B0-96A6-F75BFAA3CDF3Q40100763-0D05B29C-96EC-4285-970D-1B7B36EE9C9EQ40185161-43CE4F59-7956-4682-B16F-3ED1CE2883A4Q40532649-AF5E8DAB-9289-4D07-8DBE-DBA2570013BDQ41360656-192E0DDF-A0B0-4AEB-941D-9A2B28CFBC52Q42210601-71C77CEF-9F8F-4491-921F-131E0A75B962Q45855224-938F23E1-5A2E-408E-A235-B929217A4B57Q46372376-2EFEBE3A-B687-4CE8-A445-62AF267FB784Q47765477-5B002209-BB04-4824-BD2E-32501755D403Q48019522-8EE57637-8827-41D1-98CA-211ECD0A537BQ53423662-6679FBC5-0F49-4D6D-8899-FE8331E4EA12Q56998040-FAF457E7-48A9-4CBF-B255-85A52D0FFB88Q56998048-B212AB79-0E03-4D54-B81D-AB601926C81EQ63408452-59C1BC42-F076-49CC-8BCE-3B3F2DB0A8D4
P50
name
Martin Schlee
@en
type
label
Martin Schlee
@en
prefLabel
Martin Schlee
@en